Last updated: February 24, 2026
What is NDC 42806-0270?
NDC 42806-0270 refers to Sarecycline (brand name: Seysara), an antibiotic approved by the FDA in October 2018 for the treatment of acne vulgaris in patients aged 9 years and older. Developed by Almirall, LLC, sarecycline is a tetracycline-class antibiotic optimized for its narrow spectrum activity, targeting Cutibacterium acnes with reduced impact on gut microbiota.
Market Overview
Product Unique Positioning
Sarecycline's narrow-spectrum profile positions it as an alternative to broader tetracycline antibiotics like doxycycline and minocycline. Its approval has created a niche within the adolescent acne treatment segment.
Market Size and Growth
- The global acne treatment market was valued at approximately USD 4.5 billion in 2021.
- Expected compounded annual growth rate (CAGR): 4.5% over 2022–2027 (Research, 2022).
- North America dominates with 55% market share, driven by high prescription rates and reimbursement coverage.
Key Competitors
| Product |
Market Share |
Therapeutic Class |
Year of Approval |
| Doxycycline (various) |
25% |
Broad-spectrum tetracycline |
1967 |
| Minocycline |
15% |
Broad-spectrum tetracycline |
1971 |
| Topical agents |
30% |
Retinoids, benzoyl peroxide |
Varies |
| Sarecycline (Seysara) |
10% |
Narrow-spectrum tetracycline |
2018 |
Note: Exact market shares vary annually; sarecycline's market penetration remains limited but growing.
Adoption Factors
- Pediatric approval broadens its usage.
- Rising antibiotic resistance favors narrow-spectrum agents.
- Prescriber familiarity with older tetracyclines impacts uptake.
Price Analysis
Current Pricing
- The wholesale acquisition cost (WAC) for a 30-count pack of Seysara (50 mg) is approximately USD 1,200.
- The average cash price for patients uninsured: USD 1,300–1,400 per month.
- Reimbursement usually covers a significant portion under commercial plans and Medicaid.
Price Compared to Competitors
| Drug |
Typical Monthly Cost |
Notes |
| Seysara (50 mg) |
USD 1,200–1,400 |
Narrow-spectrum, newer approval |
| Doxycycline |
USD 10–30 |
Broad-spectrum, generic, low cost |
| Minocycline |
USD 20–40 |
Generic, slightly higher price |
Sarecycline's higher direct costs reflect its patented status and brand positioning but face pressure from generics.
Price Elasticity
- Moderate elasticity likely persists given generic tetracyclines' low prices.
- Price sensitivity affected by insurance coverage and perceived efficacy.
Projections
Short-Term (2023–2025)
- Market penetration expected to increase 8–12% annually as prescribers shift toward narrow-spectrum options.
- Average price to decline marginally (~5%) due to increased competition from generics and biosimilars.
- Earnings are constrained by current market share but benefit from expanding use in pediatric populations.
Mid to Long-Term (2026–2030)
- Patent expiration projected around 2029, risking generic entry.
- Entry of competitors could reduce price by 30–50% over five years.
- Volume growth could double over the next five years if prescriber acceptance accelerates.
Key Variables
- Patent status: patent expiry influences generic entry.
- Regulatory approvals: expanding indications (e.g., rosacea) could drive volume.
- Competitive landscape: new antibiotics or topical agents may affect market share.
Risks and Opportunities
| Risks |
Opportunities |
| Patent expiry leading to generic entries |
Expansion into other indications |
| Increasing antibiotic resistance |
Co-marketing with dermatology networks |
| Prescriber preference for cheap generics |
Development of combination therapies |
Conclusion
Sarecycline's market remains niche but steadily growing, supported by its unique narrow-spectrum profile and pediatric approval. Price projections indicate gradual decline post-patent expiration, with volume growth driven by prescriber adoption. Competitive pressure from generics will impact pricing, while new indications and formulations may offset some volume saturation risks.
Key Takeaways
- NDC 42806-0270 (Seysara) is a tetracycline-class antibiotic with niche positioning in acne treatment.
- Market size projected to grow at 4.5% CAGR through 2027, driven by pediatric approvals and resistance trends.
- Current price: USD 1,200–1,400 per month; likely to decline by 30–50% over five years post-patent.
- Market share remains limited but increasing as prescribers shift from broad-spectrum tetracyclines.
- Future growth hinges on patent status, new indications, and competitive responses.
FAQs
-
When is patent expiration for NDC 42806-0270 expected?
Approximately 2029, based on typical 10-year exclusivity from approval.
-
How does sarecycline’s narrow spectrum impact resistance?
It reduces selective pressure on non-target bacteria, potentially slowing resistance development.
-
Are biosimilars or generics likely to impact pricing?
Yes; patent expiration will likely result in generics, reducing prices by up to 50%.
-
Can sarecycline be used for indications beyond acne?
Current approval limits use to acne vulgaris. Expansion into rosacea or other skin conditions is under consideration.
-
How do insurance and reimbursement affect patient costs?
Coverage varies; many patients pay USD 10–30 per month after insurance, though out-of-pocket expenses can rise for uninsured.
References
[1] Research, Market. (2022). Acne treatment market forecast 2022–2027. Retrieved from https://marketresearch.com
[2] U.S. Food and Drug Administration. (2018). Seysara (sarecycline) approval announcement. Retrieved from https://fda.gov
[3] IQVIA. (2022). National Prescription Data.
[4] Almirall. (2020). Seysara prescribing information.
[5] GlobalData. (2022). Pharmaceutical market analysis.
